Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 143
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/22/2008
 
First Published:
7/1/1999
1.
Phase II/III Study of Standard and Novel Conditioning Therapy and Allogeneic Blood or Marrow Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
4 to 70
Other
RPCI-RP-9815
NCI-V99-1527, NCT00003816, RP 98-15
2.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
12 to 55
Pharmaceutical / Industry
GC P#02.01.001
NCT00469729
3.
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Supportive care, Treatment
Active
18 to 75
Other
0705-20 IUCRO-0196
NCT00594308
4.
Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
66 and over
NCI, NHLBI
418
BMTCTN-0201, NCT00075816
5.
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Active
2 to 55
NCI, NHLBI
385
BMT CTN 0402, U01 HL069294-05, NCT00406393
Last Modified:
10/21/2008
 
First Published:
10/25/2004
6.
Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
Under 75
NCI, Pharmaceutical / Industry
FHCRC-1825.00
5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Last Modified:
1/29/2008
 
First Published:
10/21/2005
7.
Phase I/II Study of Nonmyeloablative Conditioning Comprising Busulfan, Fludarabine, and Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 to 75
NCI
OHSU-HEM-05011-L
OHSU-210, NCT00245037
8.
Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
06-065
X05175, NCT00369226
9.
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for AML and MDS
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
70 and under
Other
2005-0508
NCT00402558
Last Modified:
7/11/2007
 
First Published:
1/5/2007
10.
Phase I/II Study of Cytoreduction Therapy Comprising Clofarabine, Melphalan, and Thiotepa Followed By Allogeneic Unmodified Hematopoietic Stem Cell Transplantion in Patients With High-Risk and/or Advanced Hematologic Malignancies or Other Diseases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
Under 55
NCI
MSKCC-06125
NCT00423514
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute